{
  "id": 15313405,
  "title": "Edward Meyercord, Extreme Networks CEO, sells $1.09m in shares",
  "url": "https://urgent.news/2026/10/18/edward-meyercord-extreme-networks-ceo-sells-1-09m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-18T00:17:34.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/edward-meyercord-extreme-networks-ceo-sells-109m-in-shares-93CH-4955704"
  },
  "original_language": "en",
  "account": "On October 1, 2026, Edward Meyercord, CEO of Extreme Networks, sold 50,000 shares of the company's stock, netting a total of $1,088,585. The sale occurred within a range of $21.27 to $22.02 per share, as the stock experienced a 10% decline over the past week. According to InvestingPro analysis, the company is still considered undervalued. Meyercord, who also serves as a director, established the trade on a pre-arranged 10b5-1 plan. As of the sale, he still holds 1,710,097 shares of Extreme Networks common stock.\n\nExtreme Networks recently reported strong fiscal fourth-quarter earnings, surpassing analyst expectations. The company's adjusted earnings per share were $0.32, compared to the expected $0.29, and revenue was $338.6 million, exceeding the forecasted $332.5 million. For the full fiscal year, revenue increased by 13% to $1.28 billion, and adjusted earnings per share rose by 26% to $1.06. The company's gross margin also improved to 62.7%, driven by pricing actions and supply-chain management.\n\nDespite positive results, the stock saw a decrease in premarket trading due to weaker growth outlook concerns for the upcoming year. UBS recently reiterated a Neutral rating on Extreme Networks, with a price target of $28.00, following meetings with the company's Chief Financial Officer. The company's strong performance is evident with nine consecutive quarters of sequential product revenue growth.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares",
        "url": "https://urgent.news/2026/10/17/maze-therapeutics-ceo-jason-coloma-sells-932-259-in-maze-shares",
        "published": "2026-10-17T23:46:17.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}